logo
  

Seelos To Use Aptar Pharma's Bidose Liquid System Device With SLS-002 Program

Seelos Therapeutics, Inc. (SEEL) has signed an agreement with AptarGroup, Inc. (ATR) for the co-exclusive use and supply of Aptar Pharma's Bidose Liquid System device for Seelos' intranasal ketamine product candidate, SLS-002, in the investigational development programs for the treatment of suicidality, depression, and Post-Traumatic Stress Disorder.

Aptar's patented BDS Liquid System has been approved by the FDA and European Medicines Agency for the delivery of other therapeutics.

Raj Mehra, Chairman and CEO of Seelos, said: "This partnership strengthens the collaboration between Seelos and Aptar, and further protects the SLS-002 franchise."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. air travel industry is going through its worst crisis since the troubled travel time during the peek pandemic struggles, with thousands of flights across the country being cancelled or getting delayed. The aviation crisis, as millions are preparing to travel during the upcoming July 4th holiday weekend, is mainly attributed to the staffing issues at airlines, ... The U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS has issued a public health alert for Siluriformes products imported by Carlstadt, New Jersey- based Grand BK Corp. The products were imported from Korea, a country ineligible to export Siluriformes products to the United States. Blount Fine Foods is recalling a limited amount of Panera at Home Southwest Corn Chowder citing undeclared wheat allergen, the U.S. Food and Drug Administration said. The recall involves a single lot of 16 oz. product with UPC Code 077958690812, lot number 042122-2K and "Use By" date of 6/30/22 that comes around 2,569 cases in total. The recall is limited to 1 SKU of 16 oz.
Follow RTT